Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897316126> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2897316126 abstract "Abstract Background: Tumors with deficient mismatch repair (dMMR) have a favorable immunological phenotype permitting exploitation by immunotherapies. We aimed to assess our institutional experience of dMMR advanced gastrointestinal (GI) cancers treated with the PD-1 inhibitor pembrolizumab. Materials and Methods: We conducted an observational cohort study of a clinical series of patients with dMMR metastatic GI cancers treated with pembrolizumab from 2015 to 2017. Patients were assessed for best response, time to and reason for discontinuation, and adverse events. Results: A total of 13 patients received at least one dose of pembrolizumab. Median age was 62 years (range 33–74 years). Diagnoses included colorectal (colorectal cancer [CRC], n = 7); extrahepatic and intrahepatic cholangiocarcinoma (EHCC,n = 2;n = 1); pancreatic (pancreatic ductal adenocarcinoma [PDAC], n = 2); and adenocarcinoma of the appendix (n = 1). Five patients received concurrent chemotherapy (FOLFOX or capecitabine) with pembrolizumab (200 mg intravenous [IV] q 2 weeks with FOLFOX or 2 mg/kg IV q 3 weeks with capecitabine). Pembrolizumab was administered 2 mg/kg IV q 3 weeks to all patients who received single-agent treatment. Eleven patients were evaluable for response assessment. Three patients had a complete response (CRC and two EHCC) and one of these patients received concomitant pembrolizumab and FOLFOX. Two patients had a partial response, one with PDAC (−88% per RECIST, continues on treatment after 15.7 months) and the other with CRC (−45% per RECIST, continues after 14.6 months), both patients received concomitant pembrolizumab and FOLFOX and are now maintained on single-agent pembrolizumab. The objective response rate was 42%. Three patients experienced immune-related adverse events requiring discontinuation. Conclusions: This single-institution case series confirms the activity of pembrolizumab in various GI cancers harboring dMMR. Future studies are warranted to determine the role of combinatorial treatment with chemotherapy and/or novel immunotherapies in this population." @default.
- W2897316126 created "2018-10-26" @default.
- W2897316126 creator A5007877290 @default.
- W2897316126 creator A5024053204 @default.
- W2897316126 creator A5027183298 @default.
- W2897316126 creator A5029563022 @default.
- W2897316126 creator A5037758727 @default.
- W2897316126 creator A5051002109 @default.
- W2897316126 creator A5052200610 @default.
- W2897316126 creator A5059616260 @default.
- W2897316126 creator A5061012285 @default.
- W2897316126 creator A5071343956 @default.
- W2897316126 date "2018-08-01" @default.
- W2897316126 modified "2023-10-18" @default.
- W2897316126 title "Pembrolizumab in Advanced Gastrointestinal Malignancies with Defective DNA Mismatch Repair: A Case Series" @default.
- W2897316126 cites W1871182306 @default.
- W2897316126 cites W1940241680 @default.
- W2897316126 cites W1984642649 @default.
- W2897316126 cites W1994993231 @default.
- W2897316126 cites W2011458181 @default.
- W2897316126 cites W2032131734 @default.
- W2897316126 cites W2050658928 @default.
- W2897316126 cites W2090109598 @default.
- W2897316126 cites W2147698761 @default.
- W2897316126 cites W2159064822 @default.
- W2897316126 cites W2210668374 @default.
- W2897316126 cites W2529308344 @default.
- W2897316126 cites W2601242481 @default.
- W2897316126 cites W2622499649 @default.
- W2897316126 cites W2739132742 @default.
- W2897316126 cites W2762685025 @default.
- W2897316126 doi "https://doi.org/10.4103/jipo.jipo_5_18" @default.
- W2897316126 hasPublicationYear "2018" @default.
- W2897316126 type Work @default.
- W2897316126 sameAs 2897316126 @default.
- W2897316126 citedByCount "0" @default.
- W2897316126 crossrefType "journal-article" @default.
- W2897316126 hasAuthorship W2897316126A5007877290 @default.
- W2897316126 hasAuthorship W2897316126A5024053204 @default.
- W2897316126 hasAuthorship W2897316126A5027183298 @default.
- W2897316126 hasAuthorship W2897316126A5029563022 @default.
- W2897316126 hasAuthorship W2897316126A5037758727 @default.
- W2897316126 hasAuthorship W2897316126A5051002109 @default.
- W2897316126 hasAuthorship W2897316126A5052200610 @default.
- W2897316126 hasAuthorship W2897316126A5059616260 @default.
- W2897316126 hasAuthorship W2897316126A5061012285 @default.
- W2897316126 hasAuthorship W2897316126A5071343956 @default.
- W2897316126 hasBestOaLocation W28973161261 @default.
- W2897316126 hasConcept C121608353 @default.
- W2897316126 hasConcept C126322002 @default.
- W2897316126 hasConcept C143998085 @default.
- W2897316126 hasConcept C2776694085 @default.
- W2897316126 hasConcept C2777701055 @default.
- W2897316126 hasConcept C2777909004 @default.
- W2897316126 hasConcept C2778260052 @default.
- W2897316126 hasConcept C2778715236 @default.
- W2897316126 hasConcept C2778822529 @default.
- W2897316126 hasConcept C2779384505 @default.
- W2897316126 hasConcept C2779984678 @default.
- W2897316126 hasConcept C2780057760 @default.
- W2897316126 hasConcept C2780962732 @default.
- W2897316126 hasConcept C2781182431 @default.
- W2897316126 hasConcept C526805850 @default.
- W2897316126 hasConcept C71924100 @default.
- W2897316126 hasConcept C90924648 @default.
- W2897316126 hasConceptScore W2897316126C121608353 @default.
- W2897316126 hasConceptScore W2897316126C126322002 @default.
- W2897316126 hasConceptScore W2897316126C143998085 @default.
- W2897316126 hasConceptScore W2897316126C2776694085 @default.
- W2897316126 hasConceptScore W2897316126C2777701055 @default.
- W2897316126 hasConceptScore W2897316126C2777909004 @default.
- W2897316126 hasConceptScore W2897316126C2778260052 @default.
- W2897316126 hasConceptScore W2897316126C2778715236 @default.
- W2897316126 hasConceptScore W2897316126C2778822529 @default.
- W2897316126 hasConceptScore W2897316126C2779384505 @default.
- W2897316126 hasConceptScore W2897316126C2779984678 @default.
- W2897316126 hasConceptScore W2897316126C2780057760 @default.
- W2897316126 hasConceptScore W2897316126C2780962732 @default.
- W2897316126 hasConceptScore W2897316126C2781182431 @default.
- W2897316126 hasConceptScore W2897316126C526805850 @default.
- W2897316126 hasConceptScore W2897316126C71924100 @default.
- W2897316126 hasConceptScore W2897316126C90924648 @default.
- W2897316126 hasLocation W28973161261 @default.
- W2897316126 hasOpenAccess W2897316126 @default.
- W2897316126 hasPrimaryLocation W28973161261 @default.
- W2897316126 hasRelatedWork W1992982990 @default.
- W2897316126 hasRelatedWork W1997133872 @default.
- W2897316126 hasRelatedWork W2008622172 @default.
- W2897316126 hasRelatedWork W2054062957 @default.
- W2897316126 hasRelatedWork W2075077394 @default.
- W2897316126 hasRelatedWork W2113757208 @default.
- W2897316126 hasRelatedWork W2414538784 @default.
- W2897316126 hasRelatedWork W2417486972 @default.
- W2897316126 hasRelatedWork W2537772349 @default.
- W2897316126 hasRelatedWork W2897316126 @default.
- W2897316126 isParatext "false" @default.
- W2897316126 isRetracted "false" @default.
- W2897316126 magId "2897316126" @default.
- W2897316126 workType "article" @default.